April 12, 2021
Article
Substudy 03B is enrolling patients with disease progression after treatment with PD-1/PD-L1 inhibitors and VEGF-tyrosine kinase inhibitors.
March 17, 2021
Article
The anonymous online survey, is meant to gain information “from urologists about the current survivorship care that is provided for survivors of prostate cancer,” according to Stacy Loeb, MD, MSc.
February 26, 2021
Article
“[Urologists are] very comfortable giving agents in the bladder, so [CG0070] really fits in line with what we give,” says investigator Edward Uchio, MD.
February 13, 2021
Article
“Among patients treated with apalutamide, molecular signatures indicative of increased immune activity, decreased vascularization, or decreased proliferative capacity at baseline were each independently associated with long-term response,” reported Felix Y. Feng, MD.